Funding opportunities

Below is a list of funding opportunities that may be of interest to the OICR research community.

Stand Up to Cancer Open Call for Ideas

Stand Up To Cancer (SU2C) is inviting proposals for a new $10 million Dream Team of top scientific investigators searching for new strategies to prevent or treat cancer. Canadian researchers are eligible.

Unlike other Dream Team grants offered by SU2C in recent years that focused on specific types of cancer, such as colorectal cancer or lung cancer, the new $10 million grant is open to any type of translational cancer research.

The SU2C Dream Team Translational Cancer Research Grant will fund a translational cancer research project that will address critical problems in patient care and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, collaborative Dream Team of expert investigators, according to the “Call for Ideas” issued to the scientific community.

The ideas may focus on particular organ sites, patient populations (such as pediatrics), or on innovative methods of treatment. Projects must be designed to accelerate the application of new preventive, diagnostic, or therapeutic approaches to the clinic that lead to patient involvement within 2-3 years from the beginning of the grant. Proposals for a Dream Team research project must present plans indicating how the work will be translated into the clinic. The ideas should be based on perceived opportunities for success as well as high-priority areas with a critical need for rapid progress beyond current medical care.

A Letter of Intent (LOI) must be submitted by noon U.S. Eastern time on Tuesday, Sept. 5, 2017, using the proposalCENTRAL website at https://proposalcentral.altum.com.

An SU2C Scientific Advisory Committee will review the Letters of Intent and select several teams to be invited to submit a full proposal. The deadline for invited full proposals is noon ET on Tuesday, Jan. 16, 2018, using the proposalCENTRAL website at https://proposalcentral.altum.com.

For more information visit: http://www.aacr.org/Funding/Pages/Funding-Detail.aspx?ItemID=69#.WUvCOhPyuEI

Cancer Therapeutics Innovation Pipeline Strategic Initiative – Request for Applications

Note: The mandatory registration phase for the 2017 competition has closed.

Background

The Ontario Institute for Cancer Research (OICR) has established the Cancer Therapeutics Innovation Pipeline (CTIP) strategic initiative to capitalize on Ontario’s expertise in cancer biology and drug discovery. CTIP aims to support the translation of Ontario discoveries into therapeutic assets with the potential for improving the lives of cancer patients.

To stimulate collaborative research with the Ontario cancer research community in the area of cancer therapeutic discovery, OICR invites applications for early stage drug discovery.

Available funding

Funding will be available to support small and large molecule projects in two stages of preclinical drug discovery: Accelerator and Incubator Projects.

Accelerator Projects

Goal: Deliver an in vitro validated target and related Hit molecules. A confirmed Hit molecule should possess features that support its potential to become a Lead molecule.


Early Accelerator Projects

Focus on target identification/validation experiments and the generation of a validated, primary assay to enable initial screening.

Funding – Up to $100,000 per year for a maximum of one year (expected completion within 6-9 months)


Late Accelerator Projects

Focus on screening using validated primary and secondary assays, with the goal of generating confirmed Hit molecules.

Funding – Up to $250,000 per year for a maximum of two years (expected completion within 15-18 months)


Incubator Projects

Goal: Deliver high-quality Lead molecules (small and/or large molecules), with demonstrated in vivo efficacy, ideally accompanied by a pharmacodynamic biomarker that correlates with target modulation.

Funding – Up to $2,000,000 over two years.

Eligibility

Investigators at Ontario academic institutions, small biotechs or start-up companies seeking support for early stage drug discovery are eligible to apply.

Timeline

Activity Date
Registration June 16, 2017 (Closed)
Full application August 15, 2017
Notification of award End of October 2017
Funding to begin December 2017 (pending execution of research agreements)

Questions

Contact OICR’s Scientific Secretariat department: scientificsecretariat@oicr.on.ca